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Abstract
Multiple lines of evidence suggest that a large portion of pancreatic cancer patients suffer from either hyperglycemia or
diabetes, both of which are characterized by high blood glucose level. However, the underlying biological mechanism of
this phenomenon is largely unknown. In the present study, we demonstrated that the proliferative ability of two human
pancreatic cancer cell lines, BxPC-3 and Panc-1, was upregulated by high glucose in a concentration-dependent manner.
Furthermore, the promoting effect of high glucose levels on EGF transcription and secretion but not its receptors in these
PC cell lines was detected by using an EGF-neutralizing antibody and RT-PCR. In addition, the EGFR transactivation is
induced by high glucose levels in concentration- and time-dependent manners in PC cells in the presence of the EGF-
neutralizing antibody. These results suggest that high glucose promotes pancreatic cancer cell proliferation via the
induction of EGF expression and transactivation of EGFR. Our findings may provide new insight on the links between high
glucose level and PC in terms of the molecular mechanism and reveal a novel therapeutic strategy for PC patients who
simultaneously suffer from either diabetes or hyperglycemia.
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Introduction
Diabetes mellitus and therioma are familiar diseases that
tremendously impact human health worldwide. Epidemiologic
evidence suggests that patients with diabetes are at a significantly
higher risk of developing many types of cancers, particularly
cancers of the pancreas, breast, liver, esophagus, and colons [1].
The pancreas is involved in both diabetes mellitus and pancreatic
cancer. Diabetes is typically divided into two major subtypes, type
1 and type 2; of these, type 2 diabetes shares many risk factors with
cancer. A recent study has demonstrated that approximately 80%
of patients with pancreatic cancer (PC) suffer from either
hyperglycemia or diabetes, both of which can be detected in the
presymptomatic phase of PC [2]. Cancer patients with diabetes
are predominantly type 2 in nature [3]. To our knowledge, few
studies to date have explored the link between cancer and type 1
diabetes. Furthermore, there is no consensus so far regarding a
causal relationship between diabetes mellitus and PC because the
nature of the association is believed to be complex. In view of
diabetes being associated with an increased risk of PC, it is a fact
that large numbers of PC patients suffer from elevated glucose
levels. When blood glucose in patients with PC is well-controlled,
patient survival time can be prolonged, suggesting that high
glucose could directly promote PC progression [4]. Our recent
study revealed that high glucose levels promoted cell proliferation
through the regulation of expression of glial cell line-derived
neurotrophic factor (GDNF) and RET in PC cells [5]. In another
study, we demonstrated that hyperglycemia, a common con-
founding factor associated with PC, may contribute to perineural
invasion [6]. However, the mechanism behind this process is still
not fully understood.
Epidermal growth factor (EGF) is a low molecular weight
(Mr=6,045) polypeptide that produces hyperproliferation of
epidermal tissues when administered to animals [7]. In PC, a
variety of growth factors are expressed at elevated levels.
Overexpression of EGF and/or TGF-a and EGFR in most PC
cells plays a crucial role in PC cell growth [8]. The concomitant
presence of EGFR and its ligand, EGF, is associated with
enhanced tumor aggressiveness and shorter survival time [9].
The biological functions of cancer cells are remarkably suppressed
when specific blockers inhibit EGFR phosphorylation. The EGF-
EGFR pathway has recently been discovered as a key therapeutic
target in lung cancer. However, there is no study concerning
whether glucose concentrations influence the expression of EGF
and EGFR in PC.
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role as a central transducer of heterologous signaling systems as a
result of its transactivation [10]. The transactivation of EGFR by
diverse stimuli, such as G protein–coupled receptors, cytokines, or
cellular stress, provides a mechanism for the EGFR to integrate
these extracellular signals and acts as a relay station to the
transcriptional machinery. High glucose has recently been shown
to transactivate EGFR in renal disease [11]. However, whether the
transactivation of EGFR occurs in PC is not clear.
To investigate how high glucose promotes proliferation of PC
cells, we investigated cell proliferation and the expression of both
EGF and EGFR in response to increasing glucose concentrations
in the PC cells. Through screening, two different differentiation
PC cells BxPC-3 (high differentiation) and Panc-1 (low differen-
tiation) were chose in the study. Furthermore, we examined the
feasibility of EGFR transactivation in PC,which participates in the
proliferation of PC cells.
Materials and Methods
Cell culture
Human PC cells BxPC-3 and Panc-1 were purchased from the
American Tissue Type Collection ([ATCC], USA). Both cell lines
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)
(Life Technologies, USA) supplemented with 10% heat-inactivat-
ed fetal bovine serum (FBS) and incubated at 37uC in a humidified
atmosphere of 5% CO2 in air. Cells were exposed to medium with
glucose concentrations varying from 5.5 to 50 mM for 12 h, 24 h,
or 48 h to study the effect of glucose concentration.
Cell proliferation assay
BxPC-3 and Panc-1 cells were seeded in 96-well tissue culture
plates at a density of 5,000–10,000 cells per well 24 h prior to
serum starvation. After serum starvation for 24 h, cells were
cultured in DMEM with concentrations of glucose ranging from
5.5 to 50 mM at 37uC. After 12 h, 24 h, or 48 h, the medium was
removed, and MTT reagent (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) was added to each well. After
incubating at 37uC for 4 h, 150 ml of DMSO was added to the
cells. Optical densities (OD) at 490 nm were measured using a
microplate reader (BIO-TEC Inc, VA). The proliferation rate was
defined as OD (cells plate)/OD (blank plate).
Immunofluorescence
Cells were fixed with 4% paraformaldehyde and then exposed
to 3% H2O2 for 10 min to block endogenous peroxidase. Cells
were incubated in nonimmune blocking serum for 15 min to block
nonspecific immunoglobulin-binding sites and then incubated with
rabbit anti-EGF polyclonal antibody (Sigma-Aldrich Inc.) over-
night at 4uC. After washing with PBS 3 times, cells were incubated
with fluorescein isothiocyanate (FITC)-conjugated goat anti-
Armenian hamster IgG (Jackson Immuno Research) for 1 h at
room temperature in a darkroom. After washing with PBS for
5 min and serum-free DMEM for another 5 min, cells were
mounted in fluoromount-G (Southern Biotech). As a negative
control, the primary antibody was substituted by antibody diluent.
Transcription-polymerase chain reaction (RT-PCR)
Total RNA from PC cells was extracted using a Fastgen200 Kit
RNA isolation system (Fastgen, Shanghai, China) according to the
manufacturer’s protocol. Total RNA was reverse-transcribed into
cDNA using the Fermentas RevertAid
TM Kit (MBI Fermentas,
Canada). EGF PCR was performed using one cycle of 94uC for
3 min, followed by 35 cycles of 94uC for 30 s, 60uC for 30 s, and
72uC for 35 s. EGFR and b-actin were amplified as follows: after
denaturing at 94uC for 3 min, 35 cycles of 94uC for 30 s, 58uC for
30 s, and 72uC for 35 s were employed. Samples were run in
triplicate, and the experiment was repeated three times. Gene
expression was quantified by normalization to b-actin. The primer
sequences were as follows:
b-actin–F: 59-ATCGTGCGTGACATTAAGGA-
GAAG-39.
b-actin–R: 59-AGGAAGAAGGCTGGAAGAGTG-39.
EGFR-F: 59-GGTGGCTGGTTATGTCCTCATTG-
39.
EGFR-R: 59-AGTTTCTGGCAGTTCTCCTCTCC-
39.
EGF-F: 59-TGTCTGCGTGGTGGTGCTTG-39.
EGF-R: 59-CTGCGACTCCTCACATCTCTGC-39.
Western blotting
Proteins were separated on 10% SDS-PAGE gels and
transferred to polyvinylidene difluoride membranes. The mem-
branes were blocked with 10% skimmed milk for 2 h at room
temperature and then incubated with rabbit anti-human antibod-
ies against EGF or EGFR (Sigma-Aldrich Inc.) or p-EGFR (Cell
Signaling) overnight at 4uC. After washing 3 times, the blots were
incubated with a goat anti-rabbit peroxidase-conjugated secondary
antibody for 1 h at room temperature. Specific binding was
detected with the enhanced chemiluminescence system (Sigma-
Aldrich Inc.).
Statistical analysis
Statistical analysis was performed using SPSS software (ver-
sion16.0, SPSS Inc. Chicago, USA). All data are represented as
mean 6 standard deviation (SD). Multiple group comparisons
were achieved by one-way analysis of variance (ANOVA) followed
by the Bonferroni post hoc test. P,0.05 was considered
statistically significant. All experiments were repeated indepen-
dently at least three times.
Results
High glucose promotes proliferation of PC cells
To investigate the influence of glucose levels on cell growth, cells
were incubated in a series of gradually increasing glucose
concentrations for 12 h, 24 h, and 48 h. In BxPC-3 cells and
Panc-1 cells, the cell proliferation rate was increased in a dose
dependent manner at glucose concentrations of 5.5 mM (as a
control), 25 mM, and 50 mM, at 12 h, 24 h, 48 h, respectively
(p,0.05) (Fig. 1A and Fig. 1B).
We determined the cell proliferation rate after treatment with
EGF-neutralizing antibody [12]. As shown in Figure 1C and 1D,
increased cell growth of BxPC-3 and Panc-1 cells treated with
EGF-neutralizing antibody was observed in response to the
glucose concentrations ranging from 5.5 mM to 50 mM
(p,0.05) (Fig. 1C and Fig. 1D). Comparing to the cells without
EGF-neutralizing antibody, cell proliferation decreased by a small
margin at glucose concentrations of 5.5 mM and 25 mM, but
showed a remarkable drop at 50 mM glucose in the EGF-
neutralizing antibody pretreated cells (Fig. 1E and 1F).
Expression of EGF in pancreatic cancer cells
It has been demonstrated that EGFR has extensive expression
on the cell surface of PC cells [8]. To examine the expression of
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EGF specific antibody to label cells, and the signals were detected
using a fluorescent microscopy. Large numbers of immunofluo-
rescence labeled granules were detected in the cytoplasm of both
cell lines (Fig. 2). These results demonstrated the expression of
EGF in PC cells.
Induction of EGF mRNA and protein, but no obvious
change in the expression of EGFR, under high glucose
stimulation
RT-PCR analysis revealed that both EGF and EGFR were
expressed in both BxPC-3 and Panc-1 cells (Fig. 3). The expression
level of EGF mRNA in both cell lines was up regulated in response
to glucose stimulation in a dose dependent manner from 5.5 to
50 mM at all time points (p,0.05). The changes between 5.5 and
25 mM were especially significant (Fig. 3A and 3B). However, the
expression of EGFR mRNA maintained a steady level irrespective
of glucose concentration or time point (p.0.05) (data not shown).
The protein expression levels of EGF and EGFR in BxPC-3 and
Panc-1 cells were determined by Western blotting (Fig. 3), and the
results were consistent with those of the RT-PCR experiments
(p,0.05) (Fig. 3C and 3D). It is well known that EGF, an essential
growth factor, exerts a critical mitogenic effect in both non-
malignant and malignant cells [13]. Hence, based on our
observation, we reason that the mechanism of action by which
high glucose exerts its effects in PC cells might via the upregulation
of EGF expression.
The transactivation of EGFR induced by high glucose
The active state of EGFR was assessed by the level of
phosphorylation of EGFR. In addition to EGF activating EGFR,
other factors, such as HB-EGF, Ang II, and aldosterone, are
known to transactivate EGFR [14,15,16]. In this study, we
determined that high glucose is also among the factors which can
induce the transactivation of EGFR. To fully abolish the effect of
EGF, cells were treated with 1 mg/ml of EGF-neutralizing
Figure 1. The influence of high glucose on cell proliferation. Cells were exposed to medium with glucose concentrations varying from 5.5 to
50 mM for 12, 24, or 48 h. MTT assay was analyzed for proliferation rates (5.5 mM as a control). (A, B) shows the proliferation rates corresponding to
different glucose concentrations in BxPC-3 and Panc-1 cells. (C, D) shows the proliferation rates corresponding to different glucose concentrations in
BxPC-3 and Panc-1 cells treated with EGF-neutralizing antibody (*p ,0.05 compared with group in 5.5 mM glucose;
# p,0.05 compared with group
in 25 mM glucose; n=8 per group). (E, F) shows the comparison of proliferation rates before and after treating with EGF-neutralizing antibody with
the different glucose concentrations in BxPC-3 and Panc-1 cells at the time point of 24 h (*p ,0.05 compared with group of without EGF neutralizing
antibody).
doi:10.1371/journal.pone.0027074.g001
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were cultured in the medium containing 25 mM glucose, the
phosphorylation level of EGFR gradually increased, in a time
dependent manner (10 min, 30 min, 60 min, 6 h, 12 h, 24 h)
(p,0.05) (Fig. 4). As a control, the phosphorylation levels in the
cells were detected in the presence of 5.5 mM glucose. The level of
EGFR phosphorylation at 5.5 mM glucose was lower compared to
the 25 mM glucose condition in a time dependent manner
(10 min, 30 min, and 60 min) (Fig. 4A and 4B).
Discussion
In this study, we showed that the proliferation of BxPC-3 and
Panc-1 cells was affected by different concentrations of glucose in a
concentration-dependent manner. We also demonstrated the
influence of glucose levels on EGF and its receptors in human
PC cell lines. Furthermore, we found that high concentrations of
glucose induced a significant increase in EGF transcription and
secretion but did not alter the expression of EGFR. In addition, we
observed that high glucose induced EGFR transactivation in a
concentration- and time-dependent manner in BxPC-3 and Panc-
1 cells in the presence of EGF-neutralizing antibody.
PC is among the most deadly of cancers; approximately 75% of
patients die within 1 year of diagnosis, and only 5% or less survive
for 5 years [17]. Due to this poor prognosis, identification of
modifiable risk factors for PC is vital. At present, there is evidence
that diabetes and hyperglycemia may be involved in the
progression of pancreatic cancer. Although long-standing diabetes
is an accepted risk factor for PC, a recent report revealed that
diabetes may be caused by PC, and that PC is a diabetogenic state
[2]. Currently, the underlying causality between diabetes mellitus
and PC has not reached a consensus. In our study, glucose
concentration may be an important causal link between diabetes
mellitus and PC as hyperglycemia exists in the tumor microen-
vironment [1,18], we have studied the influence of high glucose on
cell proliferation and investigated the potential mechanism.
Our data indicate that high glucose (25, 50 mM) could
significantly increase the proliferation of PC cells compared with
low glucose (5.5 mM). The stimulating effect on cell proliferation
in PC may be via accelerating cell cycle progression, as occurs in
rat vascular smooth muscle cells and human breast cancer cells
[19,20]. That high glucose induced EGF expression suggests there
is a pathway for cell proliferation in response to glucose
stimulation. However, when cells were pretreated with EGF-
neutralizing antibody, the increase in proliferation in response to
glucose still occurred (Fig. 1C and 1D). These data indicate that
high glucose may promote cell proliferation via pathways apart
from EGF. When comparing the proliferation rates of cells with or
without EGF-neutralizing antibody treatment, a slight decrease in
cell proliferation was found in the presence of an EGF-neutralizing
antibody at 5.5 and 25 mM glucose. Significant differences were
evident at 50 mM glucose (Fig. 1E and 1F). Therefore, EGF may
play a partial role, instead of a sole role, in the effect of low
(5.5 mM) or high glucose (25 mM) on cell proliferation. In
addition, when cells were cultured in high glucose (50 mM), EGF
may play a more important role in the stimulation of cell
proliferation than at lower glucose concentrations.
EGF induces hyperproliferation of epidermal tissues and
enhances tumor promoting actions such as proliferation and
metastasis during the progression of cancer. Therefore, EGF and
EGFR have been at the forefront of signaling research and have
been targets in the development of therapeutics [9]. EGF and
EGFR are widely expressed in malignant cancers, including PC
cells. In this study, we determined that the effects of high glucose
on cell proliferation occurred via the regulation of EGF and
EGFR mRNA and protein levels in PC. We observed that one
consequence of high glucose was the increased expression of EGF
(Fig. 3), which is highly sensitive to glucose concentration. In
Figure 2. The expression of EGF protein in BxPC-3 and Panc-1 cells. Cells were labeled with fluorescence-conjugated EGF specific antibody
(green) in both BxPC-3 (Fig. 2A, 2B) and Panc-1 cells (Fig. 2C, 2D) (2006). Granules with green fluorescence are apparent in cell plasma but not in the
nucleus in both BxPC-3 and Panc-1 cells (Fig. 2A and Fig. 2C). Fig. 2B and Fig. 2D were the nucleus staining with DAPI.
doi:10.1371/journal.pone.0027074.g002
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Our results implicated EGF as a potential factor in the effect of
high glucose on cell proliferation, but it is unlikely to have played a
sole role in this event because other cell factors, such as GDNF
and RET [5], and even unknown conditions/factors, could bring
positive effects in response to high glucose. The clear relationship
between diabetes mellitus and PC, then, still needs further
investigation.
Warburg effect, which describes that cancer cells prefer
glycolysis over oxidative phosphorylation to generate ATP, is that
cancer cells have a higher metabolism by uptake more glucose as
compared to normal cells [21]. The alterations on glucose
consumption and biosynthetic activity of amino acids, lipids and
nucleotides are metabolic changes for sustaining cell proliferation
in cancer cells [22]. Oxidative stress plays a vital role in the link
between Warburg effect and cancer cells [23]. In addition, some
researchers found that uncoupling the Warburg effect from cancer
could reduce cancer cell proliferation [21]. So the Warburg effect
in cancer cells maybe provide partly understandable network
between glucose and PC.
Figure 3. The mRNA and protein expression of EGF and EGFR in BxPC-3 and Panc-1 cells. The expression level of EGF mRNA gradually
increased in response to increasing glucose concentrations (5.5 to 50 mM) in culture medium (5.5 mM as a control) (*p ,0.05 compared with group
in 5.5 mM glucose;
# p,0.05 compared with group in 25 mM glucose; n=8 per group). The change was particularly significant between 5.5 and
25 mM glucose. However, the expression of EGFR mRNA maintained a steady remained unchanged (p.0.05). (A, B) shows EGF mRNA expression in
BxPC-3 and Panc-1 cells; (C, D) shows EGF protein expression in BxPC-3 and Panc-1 cells.
doi:10.1371/journal.pone.0027074.g003
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agonists, such as Ang II, aldosterone [14,15], b-adrenergic receptors
[16], and thrombin [24], has also been particularly well studied.
High glucose levelshave recently been shown to transactivate EGFR
in benign diseases [11]. Transactivation of EGFR by high glucose
was observed in PCcells inour study. Glucoseconcentration may be
an important causal link between diabetes mellitus and PC. We used
an EGF-neutralizing antibody to inhibit the effect of EGF on EGFR
activation. The results showed that the phosphorylation level of
EGFR was markedly increased and even occurred earlier when cells
were exposed to high concentrations of glucose (Fig. 4). In the
present study, wedemonstrated thetransactivation of EGFRbyhigh
glucose in PC cells, but we did not investigate the inner mechanism
of transactivation. An early study showed that GPCRs could
stimulate metalloproteinases, which induced cleavage of EGF-like
ligand precursors, leading to the phosphorylation of EGFR [25]. It
has also been suggested that EGFR signaling plays central roles in
cancer pathogenesis and progression [26]. Therefore, the growth
and survival of cancer cells appear to be sustained by a network of
receptors/ligands of the EGF family. We reason that EGFR
transactivation may be the main path to induce cell proliferation
in response to high glucose. Transactivation of EGFR is an
important part of cancer progression, although the process is
complex and as yet not fully understood. It is likely that EGFR is a
central component in cell signal transduction, and it induces
activation of the ras/raf/MEK/MAPK pathway [27,28,29] and
PI3K [30]. How high glucose affects the relative signaling pathway
of EGFR is still not fully understood, and further study is required.
Recently, Ke-Ping Xu et al. reported that high glucose impaired
the EGFR–phosphatidylinositol 3-kinase/Akt pathway, resulting
in delayed corneal epithelial wound healing [31]. In their studies,
high glucose reduced phosphorylation of EGFR likely through
reactive oxygen species (ROS). This result seems to run counter to
ours. The relationship between high glucose and diseases is rather
complicated. High glucose has different actions in dissimilar target
organs. For example, high glucose induces cell growth or
hyperplasia in pancreatic cancer [5], breast cancer [19] and
mesangial cells [11,32], but reduces cell growth in cornea [31] and
prostate cancer [33]. In addition, the mechanism of high glucose
on phosphorylation of EGFR is obscure and complicated. For
diabetic keratopathy, ROS is a significant and remarkable factor
in the course of high glucose impairing the phosphorylation of
EGFR, moreover, antioxidants and EGFR ligands shortage are
not neglectful factors [31]. Meanwhile, heparin-binding EGF-like
growth factor (HB-EGF), which lacks in cornea, may play an
important role in the phosphorylation of EGFR by high glucose
[31,32].
Conclusion
Our results suggest a new avenue for exploring how high levels
of glucose may contribute to PC progression. This study may
represent a paradigm shift in the relationship between diabetes
and PC. Our study found that EGF may play a partial role instead
of a sole role, in the influence of high glucose on cell proliferation.
Further, we demonstrated that high glucose transactivates EGFR
in PC cells. This result informs PC patients of the significance of
maintaining stable blood glucose and prompts exploring the
underlying mechanisms of the deteriorating effects of high glucose
in the two troublesome diseases.
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